Adrien Krug

Unraveling Vulnerabilities and Pathways Responsible for AITL Malignancy to Improve Patients’ Treatment

Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive subtype of peripheral T-cell lymphoma characterized by poor clinical outcomes following conventional CHOP-based chemotherapy and the lack of effective disease-specific therapeutic options. The disease finds its origin in...